Pharmaceutical composition for viral infections

Patent metadata

Field	Value
Publication number	US-10478407-B2
Application number	US-201916283683-A
Country	US
Kind code	B2
Filing date	Feb 22, 2019
Priority date	Feb 23, 2018
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis.

First claim

What is claimed is:

1. A method of reducing the severity or the duration of the symptoms of a viral infection selected from herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV), in a subject in need thereof, the method comprising administering to the subject in need thereof a pharmaceutical composition comprising C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride.

2. The method of claim 1 , wherein the viral infection is caused by the herpes simplex virus.

3. The method of claim 1 , wherein the symptoms of the infection are selected from lesions, pain, fever, swollen lymph nodes, and any combinations thereof.

4. The method of claim 1 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is a mixture of C12-alkyl(ethylbenzyl)dimethylammonium chloride and C14-alkyl(ethylbenzyl)dimethylammonium chloride.

5. The method of claim 1 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is C12-alkyl(ethylbenzyl)dimethylammonium chloride.

6. The method of claim 1 , wherein the pharmaceutical composition is essentially free of alkyl(ethylbenzyl)dimethyl ammonium salt having an alkyl of less than 12 carbons or more than 14 carbons.

7. The method of claim 1 , wherein the pharmaceutical composition is essentially free of benzalkonium chloride.

8. The method of claim 1 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.0001% to about 10% w/w.

9. The method of claim 1 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.001% to about 1% w/w.

10. The method of claim 1 , wherein the pharmaceutical composition is in the form of an aerosol, a solution, a lotion, a gel, an ointment, a cream, a foam, a paste, or any combinations thereof.

11. The method of claim 1 , wherein the subject in need thereof is immuno-compromised.

12. A method of preventing the spread of a viral infection selected from influenza virus, the herpes simplex virus, the human immunodeficiency virus (HIV), the hepatitis B virus, the hepatitis C virus, the human papillomavirus (HPV), the ebolavirus, and an adenovirus, in a subject in need thereof, the method comprising administering to the subject in need thereof a pharmaceutical composition comprising C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride.

13. The method of claim 12 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is a mixture of C12-alkyl(ethylbenzyl)dimethylammonium chloride and C14-alkyl(ethylbenzyl)dimethylammonium chloride.

14. The method of claim 12 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is C12-alkyl(ethylbenzyl)dimethylammonium chloride.

15. The method of claim 12 , wherein the pharmaceutical composition is essentially free of alkyl(ethylbenzyl)dimethyl ammonium salt having an alkyl of less than 12 carbons or more than 14 carbons.

16. The method of claim 12 , wherein the pharmaceutical composition is essentially free of benzalkonium chloride.

17. The method of claim 12 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.0001% to about 10% w/w.

18. The method of claim 12 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.001% to about 1% w/w.

19. The method of claim 12 , wherein the subject in need thereof is immuno-compromised.

Assignees

• The Administrators Of The Tulane Educational Fund

Inventors

• Roy Chad

Classifications

• A61P31/22

  for herpes viruses · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61K31/14 Primary

  Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205) · CPC title